Hydroxychloroquine Studies

Medical Studies Support MDs Prescribing Hydroxychloroquine for Early Stage COVID-19 and for Prophylaxis
Vladimir Zelenko, M.D. and Harvey A. Risch, M.D., PH.D. and George C. Fareed, M.D.
An Effective Treatment for Coronavirus (COVID-19)
Presented by: James M. Todaro, MD (Columbia MD, jtodaro2@gmail.com) and Gregory J. Rigano, Esq. (grigano1@jhu.edu) In consultation with Stanford University School of Medicine, UAB School of Medicine and National Academy of Sciences researchers. March 13, 2020
UNPUBLISHED DATA from China shows Chloroquine to be effective against COVID2019
More Evidence Presented for Why Hydroxychloroquine Should be Made Available, in a New Court Filing by AAPS
The Association of American Physicians & Surgeons submitted additional evidence to a federal court for why interference with hydroxychloroquine (HCQ) should end by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. FDA, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.).
Persistent hiccups as an atypical presenting complaint of COVID-19
Garrett Prince, MD⁎ and Michelle Sergel, MD
Published online 2020 Apr 18. doi: 10.1016/j.ajem.2020.04.045
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J Vincent, Eric Bergeron, Suzanne Benjannet, Bobbie R Erickson, Pierre E Rollin, Thomas G Ksiazek, Nabil G Seidah, and Stuart T Nichol
Published online 2005 Aug 22. doi: 10.1186/1743-422X-2-69


70 HCQ COVID-19 studies (42 peer reviewed)

COVID-19: The Coverup, The Cure and Key Evidence by Corey Lynn


Thanks to Phantom Shadow for producing the following list of Hydroxychloroquine Studies

Antimalarial drug confirmed effective on COVID-19
Source: Xinhua | 2020-02-17 21:07:01 | Editor: huaxia
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao, Zhenxue Tian, Xu Yang
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Published online 2020 Mar 4
Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial
Philippe Gautret, Jean-Christophe Lagiera, Philippe Parolaa, Van Thuan Hoanga, Line
Meddeba, Morgane Mailhea, Barbara Doudiera, Johan Courjone, Valérie Giordanengoh, Vera Esteves Vieiraa, Hervé Tissot Duponta, Stéphane Honoréi, Philippe Colsona, Eric Chabrièrea, Bernard La Scolaa, Jean-Marc Rolaina, Philippe Brouquia, Didier Raoult
(2020) International Journal of Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Zhaowei Chen, View ORCID ProfileJijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, View ORCID ProfileZhan Zhang
doi: https://doi.org/10.1101/2020.03.22.20040758
Treating COVID-19 with Chloroquine
Mingxing Huang, Tiantian Tang, Pengfei Pang, Man Li, Ruolan Ma, Jiahui Lu, Jingxian Shu, Yingying You, Binghui Chen, Jiabi Liang, Zhongsi Hong, Huili Chen, Ling Kong, Dajiang Qin, Duanqing Pei, Jinyu Xia, Shanping Jiang, Hong Shan
Journal of Molecular Cell Biology, Volume 12, Issue 4, April 2020, Pages 322–325, https://doi.org/10.1093/jmcb/mjaa014
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up
Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb,Jacques Sevestre, Morgane Mailhe, Barbara Doudier, Camille Aubry, Sophie Amrane, Piseth Seng, Marie Hocquart, Carole Eldin, Julie Finance, Vera Esteves Vieira, Hervé Tissot Tissot-Dupont, Stéphane Honoré, Andreas Stein, Matthieu Million; Philippe Colson, Bernard La Scola, Véronique Veit, Alexis Jacquier, Jean-Claude Deharo, Michel Drancourt, Pierre Edouard Fournier, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult
Received 3 April 2020, Accepted 4 April 2020, Available online 11 April 2020.
Empirical treatment with hydroxychloroquine and azithromycin for suspected
cases of COVID-19 followed-up by telemedicine

Rodrigo Barbosa Esper M.D., Ph.D., Rafael Souza da Silva M.D., Fernando Teiichi
Costa Oikawa M.D., Ph.D., Marcelo Machado Castro M.D., Alvaro Razuk-Filho M.D.,
Ph.D., Pedro Benedito Batista Junior M.D., Sergio Wilhelm Lotze M.D., Cleber
Nunes da Rocha M.D., Roberto de Sá Cunha Filho M.D., Saulo Emanuel Barbosa
de Oliveira M.D, Philipe Leitão Ribeiro, M.D., Valéria Cristina Vigar Martins M.D., Fernando Silva Braga Bueno M.D., Priscila Ligeiro Gonçalves Esper M.D., Eduardo Fagundes Parrillo M.D.
Affiliation/institution: Prevent Senior Institute, São Paulo, Brazil
Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths
server maintenance
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Matthieu Million, Jean-Christophe Lagier, Philippe Gautret, Philippe Colson, Pierre-Edouard Fournier, Sophie Amrane, Marie Hocquart, Morgane Mailhe, Vera Esteves-Vieira, Barbara Doudier, Camille Aubry, Florian Correard, Audrey Giraud-Gatineau, Yanis Roussel, Cyril Berenger, Nadim Cassir, Piseth Seng, Christine Zandotti, Catherine Dhiver, Isabelle Ravaux, Christelle Tomei, Carole Eldin, Hervé Tissot-Dupont, Stéphane Honoré, Andreas Stein, Alexis Jacquier, Jean-Claude Deharo, Eric Chabrière, Anthony Levasseur, Florence Fenollar, Jean-Marc Rolain, Yolande Obadia, Philippe Brouqui, Michel Drancourt, Bernard La Scola, Philippe Parola, Didier Raoult
PMID: 32387409 PMCID: PMC7199729 DOI: 10.1016/j.tmaid.2020.101738
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Membrillo, F.J.; Ramírez-Olivencia, G.; Estébanez, M.; de Dios, B.; Herrero, M.D.; Mata, T.; Borobia, A.M.; Gutiérrez, C.; Simón, M.; Ochoa, A.; Martínez, Y.; Aguirre, A.; Alcántara, F.D.A.; Fernández-González, P.; López, E.; Valle, P.; Campos, S.; Navarro, M.; Ballester, L.E.
Preprints 2020, 2020050057 (doi: 10.20944/preprints202005.0057.v2).
Hydroxychloroquine plus azithromycin: a potential interest in reducing in2 hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)
Benjamin Davido, Thibaud Lansaman, Simon Bessis, Christine Lawrence, Jean-Claude Alvarez, Hélène Mascitti, Frédérique Bouchand, Pierre Moine, Véronique Perronne, Aurélie Le Gal, Djillali Annane, Christian Perronne, Pierre De Truchis
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19
Bo Yu, Chenze Li, Peng Chen, Ning Zhou, Luyun Wang, Jia Li, Hualiang Jiang, Dao-Wen Wang
PMID: 32418114 PMCID: PMC7228868 DOI: 10.1007/s11427-020-1732-2
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities
Imtiaz Ahmad, Mohammud Alam, Ryan Saadi, Saborny Mahmud, Emily Saadi
doi: https://doi.org/10.1101/2020.05.18.20066902
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Mingxing Huang, Man Li, Fei Xiao, Pengfei Pang, Jiabi Liang, Tiantian Tang, Shaoxuan Liu, Binghui Chen, Jingxian Shu, Yingying You, Yang Li, Meiwen Tang, Jianhui Zhou, Guanmin Jiang, Jingfen Xiang, Wenxin Hong, Songmei He, Zhaoqin Wang, Jianhua Feng, Changqing Lin, Yinong Ye, Zhilong Wu, Yaocai Li, Bei Zhong, Ruilin Sun, Zhongsi Hong, Jing Liu, Huili Chen, Xiaohua Wang, Zhonghe Li, Duanqing Pei, Lin Tian, Jinyu Xia, Shanping Jiang, Nanshan Zhong, Hong Shan
National Science Review, nwaa113, https://doi.org/10.1093/nsr/nwaa113
Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon
Amanda Chamieh, Claude Afif, Gerard El-Hajj, Omar Zmerli, Isabelle Djaffar-Jureidini, Roy A. Raad, Raja Ashou, George Juvelekian, Jean-Marc Rolain, Eid Azar
doi: https://doi.org/10.1101/2020.05.28.20114835
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Violaine Guérin, Pierre Lévy, Jean-Louis Thomas, Thierry Lardenois, Philippe Lacrosse, Emmanuel Sarrazin, Natacha Regensberg de Andreis, Martine Wonner
Version 1 : Received: 30 May 2020 / Approved: 31 May 2020 / Online: 31 May 2020 (17:51:52 CEST)
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers – a Retrospective cohort
Raja Bhattacharya, Sampurna Chowdhury, Rishav Mukherjee, Anita Nandi, Manish Kulshrestha, Rohini Ghosh, Souvik Saha
doi: https://doi.org/10.1101/2020.06.09.20116806
A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications.
José A. Oteo, Pedro Marco, Luis Ponce de León, Alejandra Roncero, Teófilo Lobera, Valentín Lisa
doi: https://doi.org/10.1101/2020.06.10.20101105
HCQ beneficial as preventive drug: SMS doctors told ICMR
More than 4,300 healthcare workers including doctors and nurses have been given HCQ to help them prevent the infection as there are high chances of them getting infected while treating Covid patients.
TNN June 19, 2020, 16:30 IST
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Lan Chen, Zhen-yu Zhang, Jian-guo Fu, Zhi-peng Feng, Su-Zhen Zhang, Qiu-Ying Han, Xiao-bin Zhang, Xiong Xiao, Hui-Min Chen, Li-Long Liu, Xian-Li Chen, Yu-Pei Lan, De-Jin Zhong, Lan Hu, Jun-Hui Wang, Xing-Hua Yu, Dan-Yang She, Yong-Hong Zhu, Zhen-Yu Yin
doi: https://doi.org/10.1101/2020.06.19.20136093
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
Antonio Ferreira, Antonio Oliveira-e-Silva, Paulo Bettencourt
doi: https://doi.org/10.1101/2020.06.26.20056507
Now published in Journal of Medical Virology doi: 10.1002/jmv.26286
Risk Factors for Mortality in Patients with COVID-19 in New York City
Mikami, T., Miyashita, H., Yamada, T. et al.
J GEN INTERN MED (2020). https://doi.org/10.1007/s11606-020-05983-z
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Samia Arshad, Paul Kilgore, Zohra S. Chaudhry, Gordon Jacobsen, Dee Dee Wang, Kylie Huitsing, Indira Brar, George J. Alangaden, Mayur S. Ramesh, John E. McKinnon, William O’Neill, Marcus Zervos
Published: July 01, 2020DOI: https://doi.org/10.1016/j.ijid.2020.06.099
COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
Scholz, M.; Derwand, R.; Zelenko, V.
Preprints 2020, 2020070025 (doi: 10.20944/preprints202007.0025.v1).


Remarks by President Trump in Press Briefing | July 28, 2020
President Trump’s remarks about Kodak’s $765M loan from the U.S. to produce medicines, including Hydroxychloroquine.

America’s Frontline Doctors Summit – Session 1 (published 7/27/2020)
America’s Frontline Doctors Summit – Session 2 (published 7/27/2020)
America’s Frontline Doctors Summit – Press Conference (published 7/27/2020)
America’s Frontline Doctors Respond to High Tech Censorship (published 7/28/2020)
Tucker Carlson’s Report On Big Tech Censorship (published 7/28/2020)